EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia

Siwei Deng, Houyu Zhao, Sanbao Chai, Yexiang Sun, Peng Shen, Hongbo Lin, Siyan Zhan

Frontiers in Endocrinology · 2024

DOI: 10.3389/fendo.2024.1369908 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Endocrinology, 2024. Verfasst von Siwei Deng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Hyperglycemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A phenomenon known as legacy effect was observed that poor glycemic control at early stage of patients with newly-diagnosed type 2 diabetes (T2D) increases the risk of subsequent cardiovascular diseases (CVD). Early use of some novel anti-hyperglycemic agents, such as sodium-glucose transport protein 2 inhibitors (SGLT-2i), may attenuate this effect, but the evidence is limited.

Methods

Two retrospective cohorts of newly diagnosed T2D patients from 2010–2023 were assembled using the Yinzhou Regional Health Care Database (YRHCD) with different definitions of the early exposure period - the 1-year exposure cohort and 2-year exposure cohort, which were comprised of subjects who had HbA1c measurement data within 1 year and 2 years after their T2D diagnosis, respectively. Using Cox proportional hazards models, we examined the association between high HbA1c level (HbA1c>7%) during the early exposure period and the risk of subsequent CVD. This analysis was performed in the overall cohort and three subpopulations with different treatments during the early exposure period, including patients initiating SGLT-2i or glucagon-like peptide-1 receptor agonists (GLP-1RA), patients using dipeptidyl peptidase-4 inhibitors (DPP-4i), and patients without using SGLT-2i, GLP-1RA, and DPP-4i. Besides, subgroup analyses were performed by stratifying patients into age <55 and ≥55 years.

Results

A total of 21,477 and 22,493 patients with newly diagnosed T2D were included in the two final cohorts. Compared with patients with mean HbA1c ≤ 7% during the early exposure period, those with HbA1c>7% had higher risks of incident CVD, with a HR of 1.165 (95%CI, 1.056–1.285) and 1.143 (95%CI, 1.044–1.252) in 1-year and 2-year exposure period cohort. Compared to non-users, in patients initiating SGLT-2i/GLP-1RA within 1 or 2 years after T2D diagnosis, higher HbA1c level at baseline was not associated with CVD in both two cohorts. In subgroup analyses, results were generally consistent with the main analysis.

Conclusions

Poor glycemic control in the early stage of T2D increased later CVD risk in Chinese adults with newly diagnosed T2D. Compared to non-users, this association was smaller and non-significant in patients receiving SGLT-2i/GLP-1RA during the early stage of T2D, indicating early use of these drugs may have the potential to mitigate legacy effects of hyperglycemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHyperglycemiaGlucagon-Like Peptide-1 Receptor AgonistsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedCardiovascular DiseasesBlood GlucoseGlycated HemoglobinHypoglycemic AgentsAdultFollow-Up StudiesGlycemic Control

Stichwörter der Autor:innen

cardiovascular diseaseslegacy effectnovel anti-hyperglycemic agentspopulation-based cohorttype 2 diabetes mellitus

Substanzen

Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsBlood GlucoseGlycated HemoglobinHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
  • Center for Intelligent Public Health, Institute for Artificial Intelligence, Peking University, Beijing, China.
  • Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China.
  • School of Medicine, Chongqing University, Chongqing, China.
  • Department of Endocrinology, Peking University International Hospital, Beijing, China.
  • Big Data Center, Yinzhou District Center for Disease Control and Prevention, Ningbo, China.

Zitieren

APA

Deng, S., Zhao, H., Chai, S., Sun, Y., Shen, P., Lin, H., & Zhan, S. (2024). Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2024.1369908

Vancouver

Deng S, Zhao H, Chai S, Sun Y, Shen P, Lin H, et al. Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia. Frontiers in Endocrinology. 2024. doi:10.3389/fendo.2024.1369908

BibTeX
@article{Deng2024,
  author = {Deng, Siwei and Zhao, Houyu and Chai, Sanbao and Sun, Yexiang and Shen, Peng and Lin, Hongbo and Zhan, Siyan},
  title = {Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia},
  journal = {Frontiers in Endocrinology},
  year = {2024},
  doi = {10.3389/fendo.2024.1369908}
}
Kostenlos starten →